Alison Rand
Analyst · KBW. Ryan, your line is open
Thank you, Glenn, and good morning, everyone. Our financial results for the quarter continue to reflect revenue growth in the Term Life and Investment Savings Product segments, which have benefited from strong sales and persistency during COVID, as well as favorable equity markets. Both segments experienced lagging pretax income growth, with elevated insurance and operating expenses being a key factor. Additionally, the Senior Health segment continued to be pressured by increased churn, resulting in a loss being recognized for the quarter. Let me now expand on each of these earnings drivers. In the Term Life segment on Slide 8, operating revenues of $418 million, increased 10%, driven by a 10% increase in adjusted direct premiums. Pretax income grew 4%, as year-over-year trends were negatively impacted by normalizing persistency and elevated insurance expenses. Starting with persistency, we continue to see policy retention normalize as COVID fears subside. The business issued in the first year of that pandemic, which is now in its second duration, has demonstrated weaker performance this quarter. This is not particularly surprising, as the business was issued in the height of the pandemic. Persistency for policies issued in the last 12 months, is trending in line with pre-pandemic levels, as policies issued prior to the pandemic continue to see very strong persistency, with lapses around 20% below, lower than pre-pandemic levels. DAC amortization is most sensitive to lapses in the early durations, and as such, the persistency levels experienced this quarter, resulted in the DAC ratio rising to 15.3%, from 13.3% in the prior year period. Note that the current DAC ratio remains favorable compared to our pre-pandemic range of approximately 16% for the first quarter. On a year-over-year basis, the net impact of persistency on pretax operating income was minor, as higher DAC amortization was largely offset by continued adjusted direct premium growth and lower benefit reserve increases. Turning to mortality, the quarter experienced net COVID claims of $16 million, which was $5 million less than the prior year period. Over half of the quarter’s COVID claims were in January, with the levels steadily decreasing throughout the quarter. Assuming no new strains emerge, we expect net COVID claims of around $3 million for the second quarter. Unlike recent quarters, we did not see notable levels of excess claims for reasons other than COVID. As a result of lower excess claims, and to a lesser extent, normalizing persistency, the benefit ratio declined to 62.1% from 63.9% in the prior year period. From an operating margin perspective, the higher DAC ratio and lower benefit ratio, generally offset one another. The 100-basis point year-over-year deterioration in operating margin to 16.4%, was driven by a 23% increase in insurance expenses. The increase is largely due to adding the previously postponed biennial convention to our normal schedule of sales force leadership events for 2022. I will discuss this and other drivers of expense growth later in my remarks. As we look to the second quarter, we expect adjusted direct premiums to grow around 9%. The second quarter has historically had the strongest persistency. So, assuming this seasonality and continued normalization of lapses, we estimate the second quarter DAC amortization ratio will be 13.5% to 14%. Assuming we incur the $3 million of COVID-related net death claim, we estimate the second quarter benefit ratio to be around 59.5%. Insurance expenses are expected to be elevated in the second quarter as well, as I will discuss further later in my remarks. All in, we expect the Term Life operating margin to be between 20% and 21% in the second quarter. Turning next to the Investment and Savings Product segment on Slide 9, operating revenues of $241 million, increased 8%, while pretax income of $65 million, increased 2%. Sales-based revenues increase 5%, largely in line with the growth in revenue-generating product sales, while sales-based commissions expenses increased 9%. The increase in commission expense year-over-year, reflects the higher level of sales force bonuses implemented in 2021, in recognition of outstanding sales performance. At 1.16% for the quarter, sales-based net revenues as a percentage of revenue-generating sales, is consistent with the 2021 full year rate of 1.18. Asset-based revenues, and asset-based commission expenses, increased 12% and 14% respectively, generally in line with the increase in asset - in average client asset values. Both the first quarters of 2021 and 2022, included an acceleration of DAC amortization as a result of unfavorable market performance on Canadian segregated fund client asset values. The current period included a $1.8 million increase in amortization, whereas the prior year period included an increase of about $900,000. Turning to the Senior Health segment on Slide 10, we recognized a $19 million negative tail revenue adjustment on policies approved in prior periods. Heading into the year, we expected the January 1st renewal cycle for previous year cohorts to demonstrate weakness, but given the level of uncertainty, we waited until the commission payments came in from carriers during the first quarter, to make further tail adjustments. The tail adjustment was also driven by continued refinements to the algorithmic model that predicts expected renewal commission collections. We have adjusted the model to overweight persistency trends of recent cohorts, and believe this approach minimizes significant negative tail adjustments in the future, though we could still have some additional smaller adjustments over the next few quarters. We are also looking at how to adjust our revenue forecasting model and persistency curves, to properly reflect the rising level of existing policyholders who switch plans, but return to us to facilitate the change. We are monitoring the results of the business carefully to identify trends as early as possible. The heightened renewal churn and an increase in the revenue constraint to 10% to reflect the level of collection uncertainty, led to lower LTVs being recognized in the quarter for newly approved policies. While still too early to see a change in renewal patterns for 2021 AEP business, initial paid rates on the block were in line with expectations, and modestly improved from prior year results. We were also able to reduce contract acquisition costs for approved policies from fourth quarter levels, with the reduction efforts continuing, as Glenn mentioned earlier. There is significant seasonality within the sector, and we expect pretax losses in the second and third quarters, in the range of about $10 million per quarter, with process in the $5 million range for Q4. Importantly, we believe the actions we are taking, set us up for much stronger financial performance in 2023. With the lower anticipated agent counts and improved productivity, we expect negative cashflow to be at the low end of the range of our prior guidance of $10 million to $15 million, inclusive of the net operating loss and operating loss tax benefits recognized at the PRI level. In the Corporate and Other Distributed Products segment, the adjusted pretax operating loss of $28 million, increased $4 million year-over-year. The increased loss was driven by $3 million lower allocated net investment income due to a higher allocation of NII to the term-wide segment to support the growing block of business. Pretax operating earnings on other distributed products were down about $0.5 million year-over-year as well. Consolidated insurance and other operating expenses on Slide 11, increased 23 million or 19% year-over-year, about $8 million of which was tied to the Senior Health segment that did not exist in the prior year period. The components of the remaining $15 million or 12% increase, were as follows. About $6 million was driven by higher costs associated with in-person sales force leadership events. As we noted last quarter, we expect full year 2022 expenses to be about $9 million higher than the prior years, given that we've gone back to our in-person events. And additionally, we'll hold the previously postponed biannual convention in June this year. The elevated expenses will be recognized in the first half of 2022, with expenses associated with sales force leadership events, generally being flat year-over-year in the second half. Expenses associated with sales force leadership events, will return to historical levels in 2023. Approximately $4 million was driven by growth in our business, including higher pre-licensing related costs, as in-person classes resumed to normal levels - pre-licensing classes resumed to normal levels. Approximately $2 million was related to higher employee related costs from annual merit increases, which were somewhat offset by a high level of open positions. The remaining $3 million related to various items, including higher employee travel, given the lifting of COVID travel restrictions this year. Looking ahead, we expect second quarter insurance and other operating expenses to again be elevated, increasing about$ 25 million or 22% year-over-year. $8 million of the elevated increase is tied to the Senior Health segment that did not exist in the prior year period, and $4 million is driven by the catch-up of in-person sales force leadership events just discussed. The remaining increase is generally driven by the same recurring factors noted for first quarter. We expect year-over-year expense growth to slow significantly in the second half of ‘22, as the frequency of sales force events returns to normal, and Senior Health operating expenses are reflected in both years. On a year-over-year basis, third and fourth quarter insurance and other operating expenses, are expected to increase by about 9% and 5%, respectively. Turning next to Slide 12, the invested asset portfolio remains well diversified, with an average rating of A, and a duration of 4.9 years. During the quarter, significant increases in interest rates, led to an unrealized loss in the portfolio of $84 million, compared to an unrealized gain of $81 million at December 31 of 2021. As interest rates have continued to rise in April, fixed income prices have continued to decline. We believe the declines are predominantly interest rate-driven, and not a result of significant credit concerns. We also believe we have plenty of flexibility in the portfolio, and have the ability to hold investments until maturity, as necessary. The increase in interest rates has allowed for more attractive investment opportunities. The yield on new purchases for our life companies during the quarter, averaged 3.5% for quality of AA-, compared to 2.6% in the priority quarter. While it will take some time to reverse the impact that years of low interest rates have had on the portfolio book yield, we are optimistic about the better buying opportunities that we're seeing. Finally, on Slide 13, invested assets and cash at the holding company remain very strong at $260 million. Primerica Life’s statutory risk-based capital ratio, was estimated to be about 440% as of March 31, 2022. During the quarter, we repurchase $99 million of our common stock, which, when combined with the $19 million purchased in December, leave about $207 million remaining of our $325 million program, to be completed this year. We continue our work towards the implementation of targeted improvements to the accounting for long duration contracts, or LDTI, which will go into effect in 2023. We still plan on providing an estimate of our preliminary adjustment to the balance sheet and other qualitative information when we report second quarter results in early August. With that, Operator, I'll open the line up for questions.